Women’s Health Clinic FAQ
What is vaginal DHEA and who might consider it?
Vaginal DHEA, also called prasterone, is a daily vaginal pessary licensed in the UK for genitourinary syndrome of menopause (GSM). It is a local treatment that may be considered when non-hormonal care has not been enough or when another local option is being reviewed.
Direct answer
Vaginal DHEA, also called prasterone, is a daily vaginal pessary licensed in the UK for genitourinary syndrome of menopause (GSM). It is a local treatment that may be considered when non-hormonal care has not been enough or when another local option is being reviewed.
If the symptom pattern is getting harder to explain, you can book a consultation or ask WHC about the next step once you have a clearer record of symptoms, triggers and what you have already tried.
Educational only. Clinical suitability must be confirmed following an appropriate consultation and assessment by a qualified healthcare professional. Results vary. Not a cure.
At a glance
Vaginal DHEA, also called prasterone, is a daily vaginal pessary licensed in the UK for genitourinary syndrome of menopause (GSM). It is a local treatment that may be considered when non-hormonal care has not been enough or when another local.
Diagnostic Differentiators
Key physical and clinical parameters
What it is
a licensed daily local pessary used for GSM symptoms
What it may help
dryness, soreness, fragility and sex-related discomfort linked to GSM
What it does not replace
it does not replace red-flag review or a full menopause discussion
Best next step
review it alongside moisturisers, lubricants and other local options
Critical Progressive Risk
Educational only. Dryness, soreness and intimacy symptoms can overlap with infection, vulval skin disease, medication effects, pelvic-floor issues or deeper pelvic pain, so persistent symptoms deserve review rather than guesswork.
How vaginal DHEA fits into the GSM pathway
Vaginal DHEA is a licensed local treatment option, but it still belongs inside the same bigger menopause conversation as moisturisers, lubricants and vaginal oestrogen.
Key Overlapping Symptom Triggers
That matters because women often need help deciding whether they need a first-line non-hormonal step, a local hormone step, or a fuller review of the symptom pattern.
How the medicine works locally
Vaginal DHEA is the medicine prasterone, used locally in the vagina for GSM. The British Menopause Society says it is converted within vaginal epithelial cells into estrogens and androgens through intracrinology.
Who may discuss it
The aim is to improve mucosal thickness, secretions, elasticity and comfort in estrogen-deficient tissue. It is a local treatment, not a general menopause treatment for hot flushes or mood symptoms.
What else still matters
NHS and NICE still place lubricants, moisturisers and vaginal oestrogen in the mainstream menopause pathway, so DHEA usually sits within a wider symptom-based discussion. It may be useful when non-hormonal care has not been enough or when a person wants to discuss.
Why review stays important
Symptom improvement can take time, so it should be reviewed over weeks rather than after a few doses. Systemic HRT does not automatically rule it out, but the overall plan should still be individualised.
Why local treatment still needs context
Ongoing bleeding, unexplained pain or a cancer history should prompt proper review before assuming any local treatment is straightforward. If symptoms stay intrusive, the next step is not more guessing but a clearer menopause review.
Ongoing bleeding, unexplained pain or a cancer history should prompt proper review before assuming any local treatment is straightforward. If symptoms stay intrusive, the next step is not more guessing but a clearer menopause review.
Why vaginal DHEA still needs accurate framing
It is a real licensed option, but it is not a shortcut around diagnosis, red flags or wider menopause decision-making.
Do not normalise progression
If the pattern is becoming more intrusive, more painful or less recognisable, it deserves a proper explanation rather than repeated guesswork.
Look for overlap
Menopause-related dryness may coexist with irritation, pelvic-floor tension, infection or another diagnosis that changes the plan.
Use the least risky first step
DHEA belongs in a structured local-treatment discussion, not as a way to skip red-flag thinking or wider assessment.
Keep review thresholds low
Seek review if symptoms keep recurring, start affecting daily life or no longer respond to the same simple measures.
Why the symptom pattern matters
Ongoing bleeding, unexplained pain or a cancer history should prompt proper review before assuming any local treatment is straightforward. If symptoms stay intrusive, the next step is not more guessing but a clearer menopause review.
Ongoing bleeding, unexplained pain or a cancer history should prompt proper review before assuming any local treatment is straightforward. If symptoms stay intrusive, the next step is not more guessing but a clearer menopause review.
What makes the conversation clearer
The useful discussion is usually about symptom pattern, prior non-hormonal steps, whether another local option was tried, and what safety questions still need reviewing.
Best baseline check
Ask whether the symptom pattern, timing, triggers and wider context all point in the same direction before assuming the first explanation is the right one.
Clarify the main driver
Work out whether the main problem is dryness, fragility, irritation, pain or a mix of several layers.
Do not miss another diagnosis
Bleeding, strong odour, discharge, fever, a new lesion or severe pain should trigger broader review rather than a narrow self-care answer.
Use first-line care consistently
If moisturisers, lubricants or another local treatment have been tried, make sure the timeline and response are clear enough to judge honestly.
Know when to escalate
Escalation is appropriate when symptoms persist, worsen, recur or start affecting intimacy, confidence, sleep or daily function.
What a useful review usually adds
A good review often adds more than a prescription. It clarifies the diagnosis, the red flags, the overlap issues and the most logical next step.
That structure matters because local DHEA should sit inside a stepwise plan, not outside it.
Myths about vaginal DHEA
It can be useful, but it should not be treated as a universal fix or as a replacement for assessment.
Myth: Vaginal DHEA is a general menopause cure.
False. It is a local treatment for GSM symptoms, not a treatment for every menopause symptom.
Myth: If moisturisers help a bit, DHEA can never be relevant.
False. Some women still need a local hormonal option when non-hormonal care is not enough.
Myth: Using a local treatment removes the need for review.
False. Bleeding, unexplained pain or a mixed symptom pattern still need proper assessment.
Why the framing matters
DHEA can be useful, but only when it is placed honestly within the wider menopause pathway rather than marketed as a shortcut.
Best next step
Use it as part of a structured plan that still reviews red flags, symptom fit and whether simpler options were enough.
A practical checklist for deciding what to do next
These points help decide whether home measures still make sense or whether the picture now needs a proper review.
Pattern still fits
The symptoms are mild to moderate, recognisable and not rapidly changing.
No obvious red flags
There is no postmenopausal bleeding, severe pain, foul discharge, fever or new visible lesion.
Treatment role is clear
You know what the local treatment is for and whether it is being reviewed alongside the rest of the GSM plan.
Clear follow-up point
You know what would make you stop guessing and seek review instead.
Reassuring Signs Matrix (Green Flags)
Reasonable first steps at home usually include the following evidence-aware checks.
Indicators to Pause and Re-Evaluate (Red Flags)
Seek a clinical review sooner if the pattern is worsening or no longer looks straightforward.
Signs Demanding Immediate Clinical Evaluation
These symptoms are common, but they should not be brushed off if the pattern changes, persists or starts affecting pain, bleeding, bladder symptoms or quality of life. Access NHS 111 Support
Bleeding needs checking
Postmenopausal bleeding or repeated bleeding after sex should be assessed rather than normalised as simple dryness.
Pain may need a different explanation
Pain can also reflect infection, pelvic-floor spasm, vulval skin disease or another diagnosis that needs a different plan.
Persistent symptoms deserve options
If symptoms are ongoing, ask about evidence-based treatment rather than cycling through unsuitable over-the-counter products.
Role and timing matter
If a local treatment is being considered, review where it fits in the pathway and whether the diagnosis is clear enough first.
This safety and escalation advice is purely educational and does not replace emergency medical care. If you are experiencing severe, worsening pain, heavy active bleeding, signs of systemic infection, acute urinary retention, or sudden incontinence, please contact NHS 111, your local GP, or an urgent care centre immediately.
Deep Clinical Context & Common Patient Inquiries
Why DHEA is discussed as a local option
Vaginal DHEA is the medicine prasterone, used locally in the vagina for GSM.The British Menopause Society says it is converted within vaginal epithelial cells into estrogens and androgens through intracrinology.What should still prompt review first
The aim is to improve mucosal thickness, secretions, elasticity and comfort in estrogen-deficient tissue.- Keep DHEA inside the broader GSM pathway rather than treating it as a stand-alone cure.
- Review whether moisturisers, lubricants or vaginal oestrogen have already been tried and what actually happened.
- Escalate early if there is bleeding, unexplained pain or a cancer-history question in the background.
Authoritative UK Clinical Resources
Access peer-reviewed guidance from national healthcare bodies to support your understanding of pelvic health conditions.
Genitourinary Syndrome of Menopause (GSM) - British Menopause Society (PDF)
The full BMS consensus statement covers vaginal DHEA, lubricants, moisturisers, pelvic floor input and broader GSM treatment decisions.Read BMS guidance
Common questions about vaginal oestrogen - NHS
NHS explains that prasterone can be discussed if vaginal oestrogen is not helping, and sets realistic timelines for symptom improvement.Read NHS guidance
About vaginal oestrogen - NHS
NHS explains what vaginal oestrogen is, what it treats locally and how it differs from broader HRT.Read NHS guidance
Next step
Schedule a Confidential Specialist Evaluation
If you are deciding whether vaginal DHEA belongs in your plan, WHC can help compare it with moisturisers, lubricants and other local menopause treatments without overcomplicating the pathway.
Clinical reference materials used for this FAQ
Educational only. Individual treatment suitability can only be determined by a qualified professional after a thorough consultation and assessment. Results vary. Not a cure.
